Expertise in
5
conditions

Dr. Thomas Stanton

Hematology
Redwood Regional Medical Group Inc.
3555 Round Barn Cir, 
Santa Rosa, CA 
Expertise in
5
conditions
Redwood Regional Medical Group Inc.
3555 Round Barn Cir, 
Santa Rosa, CA 

Overview

Thomas Stanton is a Hematologist practicing medicine in Santa Rosa, California.

Dr. Stanton is highly rated in 5 conditions, according to our data. His clinical expertise encompasses Breast Cancer, Childhood Iron Deficiency Anemia, Paget Disease of the Breast, and Prostate Cancer.

He is actively involved in clinical research, participating in 5 clinical trials.

Specialties

Hematology

Licenses

Internal Medicine in CA

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

Redwood Regional Medical Group Inc.
3555 Round Barn Cir, Santa Rosa, CA 95403

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Multi-Center, Open-Label, Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anticancer Activity of Fruquintinib in Patients With Advanced Solid Tumors
A Multi-Center, Open-Label, Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anticancer Activity of Fruquintinib in Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: September 25, 2024
Intervention Type: Drug
Study Drug: Fruquintinib
Study Phase: Phase 1
A Randomized, Double-blind, Adaptive, Phase II/III Study of GSK3359609 or Placebo in Combination With Pembrolizumab for First-Line Treatment of PD-L1 Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
A Randomized, Double-blind, Adaptive, Phase II/III Study of GSK3359609 or Placebo in Combination With Pembrolizumab for First-Line Treatment of PD-L1 Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Enrollment Status: Terminated
Publish Date: July 10, 2024
Intervention Type: Drug
Study Drugs: Feladilimab, Pembrolizumab
Study Phase: Phase 3
Tomivosertib (eFT-508) in Combination With PD-1/PD-L1 Inhibitor Therapy: A Study of Subjects Administered Anti-PD-1/Anti-PD-L1 Therapy That Are Experiencing Insufficient Response to Checkpoint Inhibitor Alone
Tomivosertib (eFT-508) in Combination With PD-1/PD-L1 Inhibitor Therapy: A Study of Subjects Administered Anti-PD-1/Anti-PD-L1 Therapy That Are Experiencing Insufficient Response to Checkpoint Inhibitor Alone
Enrollment Status: Completed
Publish Date: March 22, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial Comparing CB-839 in Combination With Cabozantinib (CB-Cabo) vs. Placebo With Cabozantinib (Pbo-Cabo) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial Comparing CB-839 in Combination With Cabozantinib (CB-Cabo) vs. Placebo With Cabozantinib (Pbo-Cabo) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Enrollment Status: Completed
Publish Date: March 20, 2023
Intervention Type: Drug
Study Drugs: CB-839, Cabozantinib
Study Phase: Phase 2
An Open Label, Multi-center Protocol for U.S. Patients Enrolled in a Study of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative, High Risk Early Breast Cancer
An Open Label, Multi-center Protocol for U.S. Patients Enrolled in a Study of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative, High Risk Early Breast Cancer
Enrollment Status: Completed
Publish Date: October 11, 2021
Intervention Type: Drug
Study Phase: Phase 2
View 4 Less Clinical Trials
Similar Doctors
Expertise in
14
conditions
Dr. Elliott Vichinsky
Hematology | Oncology
Expertise in
14
conditions
Dr. Elliott Vichinsky
Hematology | Oncology

UCSF Benioff Children's Hospital Oakland

747 52nd St, 
Oakland, CA 
 (31.7 miles away)
510-428-3372
Languages Spoken:
English
See accepted insurances

Elliott Vichinsky is a Hematologist and an Oncologist practicing medicine in Oakland, California. Dr. Vichinsky is highly rated in 14 conditions, according to our data. His clinical expertise encompasses Congenital Hemolytic Anemia, Hemoglobinopathy, Hemolytic Anemia, Splenectomy, and Bone Marrow Transplant.

Expertise in
12
conditions
Dr. Ashutosh Lal
Hematology | Oncology
Expertise in
12
conditions
Dr. Ashutosh Lal
Hematology | Oncology

UCSF Benioff Children's Hospital Oakland

747 52nd St, 
Oakland, CA 
 (31.7 miles away)
510-428-3374
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Ashutosh Lal is a Hematologist and an Oncologist practicing medicine in Oakland, California. Dr. Lal is highly rated in 12 conditions, according to our data. His clinical expertise encompasses Thalassemia, Beta Thalassemia, Congenital Hemolytic Anemia, Hemoglobinopathy, and Splenectomy.

Expertise in
10
conditions
Dr. Mark Walters
Hematology | Oncology
Expertise in
10
conditions
Dr. Mark Walters
Hematology | Oncology

UCSF Benioff Children's Hospital Oakland

747 52nd St, 
Oakland, CA 
 (31.7 miles away)
510-428-3374
Languages Spoken:
English
See accepted insurances

Mark Walters is a Hematologist and an Oncologist practicing medicine in Oakland, California. Dr. Walters is highly rated in 10 conditions, according to our data. His clinical expertise encompasses Hemoglobinopathy, Sickle Cell Disease, Congenital Hemolytic Anemia, Hemolytic Anemia, and Bone Marrow Transplant.

Frequently Asked Questions about Dr. Thomas Stanton

How do I make an appointment with Dr. Thomas Stanton?

You can book an appointment with Dr. Thomas Stanton by calling their office at 707-528-1050. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Thomas Stanton a top-rated expert for Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Thomas Stanton is classified as an Advanced expert for Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Thomas Stanton specialize in?

While Dr. Thomas Stanton is a Hematology, they have specific expertise in Breast Cancer, Childhood Iron Deficiency Anemia, and Paget Disease of the Breast. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Stanton's expertise for a condition
ConditionClose
      View All 68 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile